[Assessment of changes in the lesions sizes and the incidence of complete epithelialization during the treatment of diabetic foot syndrome over a period of 4 weeks (multicenter study)]

Comparative Analysis of the Effectiveness of Some Biological Injected Wound Healing Stimulators and Criteria for Its Evaluation

PURPOSE

To investigate the comparative effectiveness of certain biological injectable stimulants for the healing of skin wounds and criteria for its assessment.

MATERIALS AND METHODS

A comparative study of the effectiveness of mesenchymal stem cells (SC group), collagen (Collagen group), and deproteinized calf blood hemoderivative (DCBH group) was carried out using an acute wound model. Control wounds were injected with isotonic sodium chloride solution (Control group). A total of four groups (28 wounds per group) were included in the study. Aged male Wistar rats were used as experimental animals. A dynamic assessment of the wound areas and edges, microvasculature assessment via laser Doppler flowmetry, histological and morphometric analyses to determine the quantitative and qualitative fibroblasts composition, as well as the degree of newly synthesized collagen maturity, was conducted on days 0, 3, 7, and 14.

RESULTS

The administration of SCs provided a rapid but short-lasting effect, whereas the administration of collagen resulted in a delayed but long-lasting wound-healing effect. DCBH resulted in little to no effect. An increase in the perfusion volume of the wound edges accelerated the regeneration process, while the level of microcirculation did not affect the number and activity of fibroblasts. The wound healing acceleration, as well as the new collagen and stratified epithelium formation and maturation, was associated with the presence of a sufficient pool of mature and active fibroblasts in the wound, and not with the number of fibroblasts.

CONCLUSION

The present results clarify the action mechanisms of the studied drugs. In addition, the application purposes and different effects of each drug on the different wound healing phases were demonstrated. An assumption on the multi-component treatment advisability under the wound condition objective assessment possibility was made. Findings from this study may assist clinicians in making an informed transition to personalized wound management and achieve better clinical outcomes.

Biological Mechanisms of Chronic Wound and Diabetic Foot Healing: The Role of Collagen

The treatment of chronic wounds is a continuously developing research focus. The problems of excessive mechanical forces, infection, inflammation, reduced production of growth factors, and lack of collagen will affect the results of treatment. The purpose of this study was to analysse the elements that lead to long-term non-healing of chronic wounds and trophic ulcers, including diabetic foot syndrome, by determining the optimal treatment algorithm. The paper presents an analysis of the world literature on the etiopathogenesis and principles of chronic wound treatment in diabetic foot syndrome. The epidemiology of chronic wounds of different genesis is presented. The issues of physiological and metabolic disorders in chronic ulcers affecting the process of wound healing are discussed. Particular attention is paid to collagen, which is a protein that forms the basis of connective tissue; collagen ensures the strength and elasticity of the skin, which confirms the importance of its role not only in aesthetics but also in the process of wound healing. Different types of collagen and their roles in the mechanisms of chronic wound healing in diabetic foot syndrome are described. The results of clinical studies evaluating the effectiveness of medical products and preparations, consisting of collagen with preserved (native collagen) and fractionated structures, in treating chronic wounds of diabetic foot syndrome are analysed. It has been shown that the use of native collagen preparations is a promising treatment for chronic ulcers and wounds, including diabetic foot syndrome, which makes it possible to increase the effectiveness of treatment and reduce the economic costs of managing these patients.

[Efficacy and safety of collagen biomaterial local application in complex treatment of the diabetic foot syndrome (final results of the multicenter randomised study)]

AIM

To evaluate the efficacy and safety of collagen biomaterial application during the 4-week follow-up of patients with diabetic foot syndrome.

MATERIAL AND METHODS

75 patients with diabetic foot (Wagner II (69.3%) and III (30.7%)) aged 30-80 years were included in the multicenter study, among them were 50.7% with the wound unhealed for 1.5-6 months and 49.3% over 6-48 months. Patients were randomized into 2 groups: 1) standard therapy (n=37), 2) the additional use of the collagen material Collost (n=38). Observation period was at least 4 weeks for each patient. The size of ulcers, results of general and biochemical blood tests, oximetry, microbiological testing, ultrasound of lower extremities vessels as well as a detailed medical history, social and functional status, level of cardiovascular comorbidity and ongoing therapy were estimated.

RESULTS

Additional use of a collagen biomaterial has led to a significant reduction ulcers of all sizes from 13.5 to 2.1 cm² (in the comparison group - from 12.5 to 7 cm²). The best dynamics have been registered in Wagner II (4.4-fold average wound area regress in Collost group, from 8.8 to 2.0 cm²; average wound area regress by 1.8 times, from 10 to 5.6 cm² in the comparison group) than in Wagner III group (in the main group from 55 to 21.3 cm²; in the control group from 36 to 32.4 cm²) and in ulcers existing less than 6 months. Treatment with biological material Collost within standard therapy after 4 weeks led to increase of complete epithelialization by 2.6% (21.1% as compared to 14.7%), while decreasing the frequency of ineffective treatment by 4.1 (7.9% in primary and 32.4% in the comparison group).

CONCLUSION

We have proved the efficacy and safety of collagen biomaterial topical application in a diabetic foot syndrome treatment.